GlassScriptPhysician profile
Peter F Cobb
NPI 1336134501
$10,654.70
in general payments reported to CMS, 2019-2025
63 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $335 · 2021: $846 · 2022: $1,496 · 2023: $1,876 · 2024: $2,380 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,905 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,905.02 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,102.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,001.66 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $807.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $721.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $545.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $506.54 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.49 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $477.02 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $434.48 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $415.86 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $376.75 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $330.87 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $235.31 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.13 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $200.84 | 2023-2025 | Cologuard Collection Kit |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.